Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture
| Autor: | B A Larder, Simon F. Lacey |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Molecular Sequence Data
Mutagenesis (molecular biology technique) Biology Virus Zalcitabine Zidovudine Serial passage medicine Emtricitabine Humans Pharmacology (medical) Cells Cultured Pharmacology Base Sequence Dideoxynucleosides Stavudine Drug Resistance Microbial RNA-Directed DNA Polymerase Virology Molecular biology HIV Reverse Transcriptase Reverse transcriptase Infectious Diseases Mutation HIV-1 Reverse Transcriptase Inhibitors HeLa Cells Research Article medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 38:1428-1432 |
| ISSN: | 1098-6596 0066-4804 |
| Popis: | We have selected a human immunodeficiency virus type 1 (HIV-1) mutant strain with a moderate (sevenfold) level of resistance to the nucleoside analog 2',3'-didehydro-2',3'-dideoxythymidine (D4T or stavudine). After serial passage of the HXB2 strain of HIV-1 in MT4 cells, a novel mutation involving two nucleotide substitutions in codon 75 of the viral reverse transcriptase, altering valine to threonine, was seen. When introduced into a wild-type HIV-1 background by site-directed mutagenesis, the T-75 mutation conferred cross-resistance to the dideoxynucleosides dideoxyinosine and dideoxycytosine as well as to 2',3'-didehydro-2',3'-dideoxycytosine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|